Novavax is trading at $11.22, down -10.63%, as speculative gains from its October 5 surge unwind.
- Novavax’s 20.08% October 5 surge followed speculation after reports of a Russian lab worker’s death. Russian officials said tests found no pathogens associated with her work, and the WHO assessed public risk as low, tempering outbreak concern behind the vaccine-stock rally.
- Biotech was down 2.50%; no new Novavax-specific catalyst was identified. The decline appears to reverse speculative gains, with sector weakness adding pressure.